These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 24170325)

  • 1. The effect of lansoprazole, an OCT inhibitor, on metformin pharmacokinetics in healthy subjects.
    Ding Y; Jia Y; Song Y; Lu C; Li Y; Chen M; Wang M; Wen A
    Eur J Clin Pharmacol; 2014 Feb; 70(2):141-6. PubMed ID: 24170325
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of proton pump inhibitors on metformin pharmacokinetics and pharmacodynamics.
    Kim A; Chung I; Yoon SH; Yu KS; Lim KS; Cho JY; Lee H; Jang IJ; Chung JY
    Drug Metab Dispos; 2014 Jul; 42(7):1174-9. PubMed ID: 24764147
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effects of rabeprazole on metformin pharmacokinetics and pharmacodynamics in Chinese healthy volunteers.
    Liu G; Wen J; Guo D; Wang Z; Hu X; Tang J; Liu Z; Zhou H; Zhang W
    J Pharmacol Sci; 2016 Dec; 132(4):244-248. PubMed ID: 27245553
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Effect of Famotidine, a MATE1-Selective Inhibitor, on the Pharmacokinetics and Pharmacodynamics of Metformin.
    Hibma JE; Zur AA; Castro RA; Wittwer MB; Keizer RJ; Yee SW; Goswami S; Stocker SL; Zhang X; Huang Y; Brett CM; Savic RM; Giacomini KM
    Clin Pharmacokinet; 2016 Jun; 55(6):711-21. PubMed ID: 26597253
    [TBL] [Abstract][Full Text] [Related]  

  • 5. N(1)-methylnicotinamide as an endogenous probe for drug interactions by renal cation transporters: studies on the metformin-trimethoprim interaction.
    Müller F; Pontones CA; Renner B; Mieth M; Hoier E; Auge D; Maas R; Zolk O; Fromm MF
    Eur J Clin Pharmacol; 2015 Jan; 71(1):85-94. PubMed ID: 25552403
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A drug-drug interaction study to evaluate the impact of peficitinib on OCT1- and MATE1-mediated transport of metformin in healthy volunteers.
    Shibata M; Toyoshima J; Kaneko Y; Oda K; Nishimura T
    Eur J Clin Pharmacol; 2020 Aug; 76(8):1135-1141. PubMed ID: 32472157
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of the multidrug and toxin extrusion (MATE) transporter by pyrimethamine increases the plasma concentration of metformin but does not increase antihyperglycaemic activity in humans.
    Oh J; Chung H; Park SI; Yi SJ; Jang K; Kim AH; Yoon J; Cho JY; Yoon SH; Jang IJ; Yu KS; Chung JY
    Diabetes Obes Metab; 2016 Jan; 18(1):104-8. PubMed ID: 26381793
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Verapamil decreases the glucose-lowering effect of metformin in healthy volunteers.
    Cho SK; Kim CO; Park ES; Chung JY
    Br J Clin Pharmacol; 2014 Dec; 78(6):1426-32. PubMed ID: 25060604
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of cephalexin on the pharmacokinetics of metformin in healthy human volunteers.
    Jayasagar G; Krishna Kumar M; Chandrasekhar K; Madhusudan Rao C; Madhusudan Rao Y
    Drug Metabol Drug Interact; 2002; 19(1):41-8. PubMed ID: 12222753
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of the ingestion of Ginkgo biloba extract (EGb 761) on the pharmacokinetics of metformin in non-diabetic and type 2 diabetic subjects--a double blind placebo-controlled, crossover study.
    Kudolo GB; Wang W; Javors M; Blodgett J
    Clin Nutr; 2006 Aug; 25(4):606-16. PubMed ID: 16698134
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proton pump inhibitors do not impair the effectiveness of metformin in patients with diabetes.
    Flory J; Haynes K; Leonard CE; Hennessy S
    Br J Clin Pharmacol; 2015 Feb; 79(2):330-6. PubMed ID: 25199921
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Effect of Nizatidine, a MATE2K Selective Inhibitor, on the Pharmacokinetics and Pharmacodynamics of Metformin in Healthy Volunteers.
    Morrissey KM; Stocker SL; Chen EC; Castro RA; Brett CM; Giacomini KM
    Clin Pharmacokinet; 2016 Apr; 55(4):495-506. PubMed ID: 26507723
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proton pump inhibitors inhibit metformin uptake by organic cation transporters (OCTs).
    Nies AT; Hofmann U; Resch C; Schaeffeler E; Rius M; Schwab M
    PLoS One; 2011; 6(7):e22163. PubMed ID: 21779389
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A non-linear pharmacokinetic-pharmacodynamic relationship of metformin in healthy volunteers: An open-label, parallel group, randomized clinical study.
    Chung H; Oh J; Yoon SH; Yu KS; Cho JY; Chung JY
    PLoS One; 2018; 13(1):e0191258. PubMed ID: 29342199
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tolerability and pharmacokinetics of metformin and the dipeptidyl peptidase-4 inhibitor sitagliptin when co-administered in patients with type 2 diabetes.
    Herman GA; Bergman A; Yi B; Kipnes M;
    Curr Med Res Opin; 2006 Oct; 22(10):1939-47. PubMed ID: 17022853
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug interaction studies with dexlansoprazole modified release (TAK-390MR), a proton pump inhibitor with a dual delayed-release formulation: results of four randomized, double-blind, crossover, placebo-controlled, single-centre studies.
    Vakily M; Lee RD; Wu J; Gunawardhana L; Mulford D
    Clin Drug Investig; 2009; 29(1):35-50. PubMed ID: 19067473
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metformin and daclatasvir: absence of a pharmacokinetic-pharmacodynamic drug interaction in healthy volunteers.
    Smolders EJ; Colbers A; de Kanter CTMM; Velthoven-Graafland K; Wolberink LT; van Ewijk-Beneken Kolmer N; Drenth JPH; Aarnoutse RE; Tack CJ; Burger DM
    Br J Clin Pharmacol; 2017 Oct; 83(10):2225-2234. PubMed ID: 28474741
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of Ondansetron on Metformin Pharmacokinetics and Response in Healthy Subjects.
    Li Q; Yang H; Guo D; Zhang T; Polli JE; Zhou H; Shu Y
    Drug Metab Dispos; 2016 Apr; 44(4):489-94. PubMed ID: 26825640
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A clinical study to examine the potential effect of lansoprazole on the pharmacokinetics of bosutinib when administered concomitantly to healthy subjects.
    Abbas R; Leister C; Sonnichsen D
    Clin Drug Investig; 2013 Aug; 33(8):589-95. PubMed ID: 23839484
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of the effect of multiple doses of lansoprazole on the pharmacokinetics and safety of ponatinib in healthy subjects.
    Narasimhan NI; Dorer DJ; Davis J; Turner CD; Sonnichsen D
    Clin Drug Investig; 2014 Oct; 34(10):723-9. PubMed ID: 25145453
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.